A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT01142492
• Date of registration: 10/06/2010
• Prospective Registration: No
• Primary sponsor: Merck KGaA
• Public title: A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) TOURIMS
• Scientific title: Postmarketing Surveillance Study on the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis With Interferon Beta 1a (Rebif®)
• Date of first enrolment: January 2005
• Target sample size: 403
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT01142492
• Study type: Observational
• Study design: Observational Model: Cohort, Time Perspective: Prospective
• Phase: N/A

Contacts

• Name: Dr. Norbert Zessack
• Affiliation: Merck Serono GmbH, Germany

Key inclusion & exclusion criteria

Inclusion Criteria:

- Subjects with clinically diagnosed multiple sclerosis (MS) and relapses

Exclusion Criteria:

- Subjects with secondary progressive MS (SPMS) without relapses, pregnant or
breastfeeding subjects, and subjects with contra- indications.

- Subjects with systemic concomitant diseases (e.g. diabetes, heart disease, liver
disease, or renal disease)



Age minimum: N/A
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Relapsing-Remitting Multiple Sclerosis

Intervention(s)

Drug: Interferon beta-1a

Primary Outcome(s)

Subjects' compliance to treatment [Time Frame: 24 months]

Secondary ID(s)

IMP28157

Source(s) of Monetary Support

Please refer to primary and secondary sponsors